Institut Pasteur De Lille

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Ferring B.v.

Univ. of Tennessee Research Corp.

Andre Tartar

Helene Gras-Masse

Christian Sergheraert

Christophe Boutillon

Jean-Paul Levy

Elisabeth Gomard

Remy Magne

Frederic Martinon

Louis A Chedid

David Michael Evans

Francoise Marguerite Audibert

Edwin H Beachey

Andre Capron

Patrice Boquet

Edith Duflot

Helene Gras

Anabela Duflot

Michel Jolivet

Pierrette Maes

Corinne Mercier

Marie-France Cesbron

The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein Ris H or CN; Ris selected from CHR, CHCHRand C(R)(R)&#x2014;X&#x2014;(CH)R; Rand Rare each independently selected from H and Me; Ris selected from CON(R)(R), N(R)C(&#x2550;O)R, N(R)C(&#x2550;S)R, N(R)SORand N(R)R; Rand Rare each independently R(CH)or together they are &#x2014;(CH)&#x2014;Z&#x2014;(CH)&#x2014; or CH&#x2014;o&#x2014;CH&#x2014;Z&#x2014;CH&#x2014;; Ris H or Me; Ris selected from R(CH), R(CH)O and N(R)(R); Ris R(CH); Ris selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; Ris selected from HNCH(R)CO, HNCH(R)CONHCH(R)CO, C(R)&#x2550;C(R)CORand ROCO; R, Rand Rare selected from the side chains of the proteinaceous amino acids; Ris selected from H, lower alkyl (C&#x2013;C) and phenyl; Ris selected from H and lower alkyl (C&#x2013;C); Ris selected from H, lower alkyl (C&#x2013;C), OH, O-(lower alkyl (C&#x2013;C)) and phenyl; Ris selected from lower alkyl (C&#x2013;C), optionally substituted phenyl and RC(&#x2550;O)OC(R)(R); R, Rand Rare each independently selected from H and lower alkyl (C&#x2013;C); Z is selected from a covalent bond, &#x2014;(CH)&#x2014;, &#x2014;O&#x2014;, &#x2014;SO&#x2014; and &#x2014;N(R)&#x2014;; Xis S or CH; Xis O, S or CH; a is 1, 2 or 3; b is 0&#x2013;3; c is 1 or 2; and d is 0, 1 or 2. 

Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one tigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups. Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide fragment having approximately between 10 and 40 amino acids and comprising at least one antigenic determinant and also comprising one or more chains derived from fatty acids and one or more modified steroid groups useful for immunizing a human or animal body against pathogenic agents such as viruses or parasites which fragment is preferably a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Cytotoxic T lymphocyte-inducing lipopeptides and methods of use

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one antigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups. Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses. DA.

Cloning of gene encoding the GP28.5 protein of toxoplasma gondii;

Peptide fragment of M protein of S. pyrogenes elecit opsonic antibodies which are type-specific for type 24 streptococci.

Synthetic peptide compounds

The invention relates to novel synthetic peptides, process for their peparation and their application to the production of antibodies. These peptides include at the most 18 amino-acids and at the least 4 amino-acids in which n is equal to 1 or 2, and when n equals 1 the peptidic sequence P is contained in the following peptidic chain:

Synthetic ST toxin, process for its preparation and its use as a

Growing community of inventors

Vitry en Artois, France

Andre Tartar